Related Experiment Video
Updated: Jul 16, 2026
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
Platelet glycoprotein VI: a novel marker for acute coronary syndrome
Boris Bigalke1, Harald Langer, Tobias Geisler
1Medizinische Klinik III, Eberhard Karls-Universität Tübingen, Tübingen, Germany.
Insights
Platelet glycoprotein VI (GPVI) expression is elevated in acute coronary syndrome (ACS) patients, preceding myocardial injury markers. Measuring GPVI may identify patients at risk for thrombosis before evident ischemia.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Thrombosis Research
Background:
- Platelet glycoprotein VI (GPVI) is a key receptor in arterial thrombosis.
- Understanding GPVI's role in acute coronary syndrome (ACS) is crucial for early diagnosis.
Purpose of the Study:
- To investigate platelet GPVI surface expression in patients with stable angina versus ACS.
- To assess the correlation of GPVI expression with platelet activation markers and myocardial injury indicators.
Main Methods:
- Flow cytometry was used to quantify platelet surface expression of GPVI and activation markers (P-selectin, GPIbalpha).
- Patient groups included those with stable angina, ACS, and healthy controls.
Main Results:
- Patients with ACS exhibited significantly higher platelet GPVI expression compared to stable angina patients and controls.
- GPVI expression strongly correlated with CD62P (P-selectin) levels.
- Elevated GPVI was observed in ACS patients hours before troponin or creatine kinase indicated myocardial necrosis.
Conclusions:
- Platelet GPVI is an early indicator of ACS, potentially preceding detectable myocardial injury.
- Measuring platelet GPVI may serve as a valuable biomarker for identifying patients at risk of thrombotic events before clinical manifestation of ischemia.
Abstract:
The platelet collagen receptor glycoprotein (GP) VI is critical for the formation of arterial thrombosis. GPVI platelet surface expression was examined in patients with stable angina and in patients with acute coronary syndrome (ACS). Surface expression of platelet activation markers such as P-selectin, GPIbalpha, and platelet GPVI was determined by flow cytometry. Patients with ACS showed a significantly enhanced GPVI expression compared with patients with stable angina and healthy controls. The expression of GPVI correlated well with CD62P. Elevated platelet GPVI expression was associated with ACS independent of markers of myocardial necrosis such as troponin and creatine kinase. In ACS, platelet surface GPVI expression was already elevated several hours before troponin and creatine kinase indicated myocardial injury. We conclude that the determination of the platelet-specific thrombotic marker GPVI may help to identify patients at risk before myocardial ischemia is evident.
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:30Acute Coronary Syndrome I: Introduction
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...